Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
limited-time offer
Enjoy this offer
* See conditions on site
Capitalization 131B 146B P/E ratio 2024 *
20x
P/E ratio 2025 * 15.7x
Enterprise value 139B 155B EV / Sales 2024 *
2.95x
EV / Sales 2025 * 2.68x
Free-Float
87.21%
Yield 2024 *
3.66%
Yield 2025 * 3.87%
More valuation ratios * Estimated data
Dynamic Chart
1 day-0.61%
1 week+3.43%
Current month+3.68%
1 month+11.32%
3 months+15.69%
6 months+19.77%
Current year+16.89%
More quotes
1 week
102.94
Extreme 102.94
106.14
1 month
93.15
Extreme 93.15
106.14
Current year
84.93
Extreme 84.93
106.14
1 year
80.60
Extreme 80.6
106.14
3 years
76.45
Extreme 76.45
106.66
5 years
67.65
Extreme 67.65
106.66
10 years
62.50
Extreme 62.5
106.66
More quotes
Director TitleAgeSince
Chief Executive Officer 56 19-08-31
Director of Finance/CFO 62 Mar. 31
Chief Tech/Sci/R&D Officer 47 -
Manager TitleAgeSince
Director/Board Member 62 13-05-02
Director/Board Member 71 14-04-30
Director/Board Member 59 19-04-29
More insiders
Name Weight AuM 1st Jan change Investor Rating
6.31% 5 M€ +4.56%
3.66% 132 M€ -.--%
More ETFs: Sanofi
Add to a list
Change 5d. change 1-year change 3-years change Capi. ($)
-0.61%+3.43%+5.95%+19.43%146B
-3.55%-2.92%+63.52%+251.69%822B
-2.16%-4.01%+33.76%+181.19%583B
-1.42%+0.46%+2.68%-5.74%397B
-2.11%-1.19%+32.01%+72.78%341B
+2.41%+0.96%+10.31%+53.49%301B
-3.88%-5.53%+16.80%+47.37%256B
-1.07%-3.22%+8.78%-24.28%262B
-1.99%-2.95%+12.67%+18.64%236B
-1.90%-2.01%+27.70%+43.29%174B
Average -0.96%-1.70%+21.42%+65.79% 351.77B
Weighted average by Cap. -0.82%-2.13%+29.06%+105.63%
See all sector performances
2024 *2025 *
Net sales 47.26B 52.54B 50.62B 56.28B
Net income 6.65B 7.4B 8.93B 9.93B
Net Debt 7.86B 8.74B 4.19B 4.66B
More financial data * Estimated data
Logo Sanofi
Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows: - pharmaceutical products (70.6%): prescription drugs in the areas of specialty medicine (59.3% of net sales; for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases) and general medicine (40.7%; mainly for the treatment of diabetes and cardiovascular diseases); - human vaccines (17.4%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas; - consumer health products (12%). At the end of 2023, the group had 54 production sites throughout the world. Net sales are distributed geographically as follows: France (5.5%), Europe (18.6%), the United States (43%), North America (1.6%) and other (31.3%).
Employees
86,088
More about the company
Date Price Change Volume
24-09-06 105.04 +0.11% 81,145
24-09-05 104.92 -0.61% 1,689,634
24-09-04 105.56 +1.48% 2,023,127
24-09-03 104.02 -0.80% 1,678,628
24-09-02 104.86 +3.62% 2,240,356

Real-time Euronext Paris, September 05, 2024 at 11:35 am EDT

More quotes
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
104.92EUR
Average target price
109.95EUR
Spread / Average Target
+4.79%
Consensus
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW